Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Zetiq Reports Success In Clinical Trial Aimed For Early Identification Of Cervical Cancer
Zetiq, a subsidiary of Bio-Light Ltd. (TASE:BOLT), reports the successful completion of a clinical trial to validate feasibility of early identification of cervical cancer.
generic viagra online
Opinion Pieces Discuss Whether Current Efforts To Fix Health Costs Will Produce Sufficient Savings
David Brooks, New York Times: Health care costs have become "the crucial issue of [President Obama"s] whole presidency," Times columnist Brooks writes. According to Brooks, Obama"s original plan was to fund his priorities, including education and energy, with debt that would be paid off with future savings resulting from health care reform. Brooks writes that Obama"s aides have been discussing "game-changers" -- such as health information technology, wellness programs, preventive medicine, comparative effective measures and altering reimbursement policies -- that would result in cost reductions. However, Brooks writes that most experts do not think such efforts would "produce much in the way of cost savings over the next 10 years" and that "nobody is sure" the efforts would "ever produce significant savings." Brooks writes that because "there are deep structural forces, both in Medicare and the private insurance market" that make it "nearly impossible to put together a majority coalition for a bill" challenging those structures, reform efforts this year likely will produce a "medium-size bill that expands coverage to some groups but does relatively little to control costs." Brooks concludes, "Without serious health cost cuts," Obama"s agenda "will hasten fiscal suicide" (Brooks, New York Times, 5/15).
News of the day
FDA Approves NovoLog(R) Labeling Update - Increasing The Time Patients Can Use And Store NovoLog(R) In Their Pumps From Two Days To Six Days
Diabetes patients taking NovoLog® (insulin aspart [rDNA origin] injection) can now use the insulin in their pump for up to six days following the U.S. Food and Drug Administration (FDA) approval of a labeling change, diabetes care company Novo Nordisk announced today.[i] The previous label allowed for NovoLog® to be stored in the pump reservoir for two days. This makes NovoLog® the first and only rapid-acting insulin with this extended in-use time.
Mental Health

Collaboration Between NC State And UNC Lineberger To Combat Non-Hodgkin Lymphoma In Human And Canine Patients

What do a college of veterinary medicine and a cancer treatment and research center have in common? The answer may be as plain as the nose on your dog"s face. Researchers from North Carolina State University"s College of Veterinary Medicine and the University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center are combining their expertise to pinpoint the cause of -- and improve treatments for -- non-Hodgkin lymphoma in human and canine patients. The dog is an excellent model to study human cancer, particularly lymphoma. The disease is biologically similar in human and canine patients, but is much easier to narrow down problematic areas in a dog"s genome because the genetic variation among dogs of the same breed is so much lower than genetic variation in humans. These factors, coupled with the publication of the human and canine genomes, make the dog the perfect candidate for this collaborative research. Drs. Steven Suter, professor of clinical sciences, and Matthew Breen, professor of genomics, along with statistics professor Dr. Alison Motsinger-Reif and Dr. Dahlia Nielsen, research assistant professor of genetics, lead the NC State component. Researchers at UNC Lineberger are led by Dr. Kristy Richards, geneticist and clinical oncologist. The team is recruiting dogs diagnosed with lymphoma to collect tissue samples for study. A simple and speedy procedure at the NC State Veterinary Teaching Hospital, the collection causes no discomfort to the dog and owners receive $1,000 for their pet"s participation. Labs from both institutions will study tissue samples from human and canine patients, with the hope of creating a genomic "profile" of non-Hodgkin lymphoma that would give oncologists and veterinarians greater insight into the disease"s biology, and improve their ability to diagnose the illness early. "Non-Hodgkin lymphoma ranks fifth in cancer deaths among human patients, and the mortality rate for dogs is even higher," Suter says. "By combining the strengths of our programs, we expect to enhance our understanding of the disease and speed improved treatments for people and pets. This is another example of "One Health," the concept of comparative medicine that acknowledges human and animal health relies on a common pool of medical and scientific knowledge and is supported by overlapping technologies and discoveries." Richards adds, "Traditionally, lymphoma researchers have used laboratory mouse models of lymphoma, but it would be advantageous to study lymphoma in a large animal model with spontaneously occurring lymphomas that more closely mimic the situation in humans. There are very few places in the country where a top-rate veterinary program is in such proximity to a top-rate medical school with a comprehensive cancer center. We aim to take full advantage of this partnership to discover, develop and test new treatments much faster than could be done in either organism alone." Dianne Shaw University of North Carolina School of Medicine


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009